IN2014DN06567A - - Google Patents
Info
- Publication number
- IN2014DN06567A IN2014DN06567A IN6567DEN2014A IN2014DN06567A IN 2014DN06567 A IN2014DN06567 A IN 2014DN06567A IN 6567DEN2014 A IN6567DEN2014 A IN 6567DEN2014A IN 2014DN06567 A IN2014DN06567 A IN 2014DN06567A
- Authority
- IN
- India
- Prior art keywords
- kinase
- inhibitors
- compounds
- heteroaryl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54249004P | 2004-02-06 | 2004-02-06 | |
| US62493704P | 2004-11-04 | 2004-11-04 | |
| PCT/US2005/003728 WO2005077945A2 (en) | 2004-02-06 | 2005-02-04 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06567A true IN2014DN06567A (pl) | 2015-07-10 |
Family
ID=34864498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6567DEN2014 IN2014DN06567A (pl) | 2004-02-06 | 2005-02-04 |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1711481B2 (pl) |
| JP (2) | JP5148115B2 (pl) |
| KR (2) | KR101310427B1 (pl) |
| AR (1) | AR047533A1 (pl) |
| AT (1) | ATE453630T1 (pl) |
| AU (1) | AU2005212405B2 (pl) |
| BR (1) | BRPI0507476B8 (pl) |
| CA (1) | CA2555291C (pl) |
| CY (1) | CY1109907T1 (pl) |
| DE (1) | DE602005018601D1 (pl) |
| DK (1) | DK1711481T4 (pl) |
| ES (1) | ES2337272T5 (pl) |
| GE (1) | GEP20094804B (pl) |
| HK (1) | HK1091835A1 (pl) |
| HR (1) | HRP20100166T4 (pl) |
| IL (1) | IL177280A (pl) |
| IN (1) | IN2014DN06567A (pl) |
| NO (1) | NO338049B1 (pl) |
| NZ (1) | NZ548613A (pl) |
| PE (1) | PE20050691A1 (pl) |
| PL (1) | PL1711481T5 (pl) |
| PT (1) | PT1711481E (pl) |
| RU (1) | RU2382039C2 (pl) |
| SI (1) | SI1711481T2 (pl) |
| TW (1) | TWI338004B (pl) |
| WO (1) | WO2005077945A2 (pl) |
| ZA (1) | ZA200606242B (pl) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005502643A (ja) | 2001-08-10 | 2005-01-27 | ノバルティス アクチエンゲゼルシャフト | 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用 |
| WO2004098528A2 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
| TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US7652146B2 (en) | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| TW200600513A (en) | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| GEP20104927B (en) * | 2005-05-05 | 2010-03-25 | Bristol Myers Squibb Co | Formulations of a src/abl inhibitor |
| ES2342194T3 (es) | 2005-08-05 | 2010-07-02 | Bristol-Myers Squibb Company | Preparacion de derivados de acido 2-amino-tiazol-5-carboxilico. |
| US20070105867A1 (en) * | 2005-09-21 | 2007-05-10 | Bristol-Myers Squibb Company | Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
| US20070219370A1 (en) * | 2006-03-15 | 2007-09-20 | Bristol-Myers Squibb Company | Process for preparing n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino] -5-thiazolecarboxamide and related metabolites thereof |
| EP2061468A4 (en) | 2006-09-11 | 2011-05-04 | Curis Inc | TYROSINE KINASE INHIBITORS CONTAINING ZINC BINDING CHARACTERISTIC GROUP |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| JP2010539156A (ja) | 2007-10-23 | 2010-12-16 | テバ ファーマシューティカル インダストリーズ リミティド | ダサチニブ多形体およびその調製プロセス |
| WO2010062715A2 (en) * | 2008-11-03 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
| WO2010067374A2 (en) * | 2008-12-08 | 2010-06-17 | Hetero Research Foundation | Polymorphs of dasatinib |
| WO2010129208A1 (en) * | 2009-05-05 | 2010-11-11 | Merck Sharp & Dohme Corp. | P38 kinase inhibiting agents |
| CN101812060B (zh) * | 2010-02-02 | 2011-08-17 | 南京卡文迪许生物工程技术有限公司 | 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物 |
| EP2359813A1 (en) | 2010-02-04 | 2011-08-24 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
| CN102250084A (zh) * | 2010-02-08 | 2011-11-23 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
| JP5589097B2 (ja) * | 2010-02-08 | 2014-09-10 | 南京▲か▼文迪許生物工程技術有限公司 | ダサチニブ多結晶体、並びにその調製方法及び薬物組成物 |
| WO2013065063A1 (en) | 2011-11-03 | 2013-05-10 | Cadila Healthcare Limited | Anhydrous form of dasatinib, process for its preparation and its use |
| EP2861589B1 (en) * | 2012-06-15 | 2017-05-17 | Basf Se | Multicomponent crystals comprising dasatinib and selected cocrystal formers |
| CN102827156A (zh) * | 2012-09-11 | 2012-12-19 | 湖南欧亚生物有限公司 | 一种达沙替尼的新的工业合成方法 |
| CN103819469A (zh) * | 2012-11-16 | 2014-05-28 | 重庆医药工业研究院有限责任公司 | 一种达沙替尼的晶型及其制备方法 |
| CZ306598B6 (cs) | 2012-12-06 | 2017-03-22 | Zentiva, K.S. | Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu |
| CN103880833B (zh) * | 2012-12-19 | 2018-04-06 | 北京本草天源药物研究院 | 达沙替尼一水合物的新晶形及其制备方法和药物组合物 |
| US9365526B2 (en) | 2012-12-31 | 2016-06-14 | Sun Pharmaceutical Industries Limited | Process for the preparation of dasatinib and its intermediates |
| CN103319476B (zh) * | 2013-06-13 | 2015-12-02 | 济南德爱医药技术有限公司 | 一种激酶抑制剂 |
| EP3024831A2 (en) * | 2013-07-25 | 2016-06-01 | Basf Se | Salts of dasatinib in amorphous form |
| JP6501773B2 (ja) * | 2013-07-25 | 2019-04-17 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 結晶形態のダサチニブの塩 |
| CN104341410A (zh) * | 2013-08-09 | 2015-02-11 | 上海科胜药物研发有限公司 | 一种达沙替尼新晶型及其制备方法 |
| CN103483289B (zh) * | 2013-09-06 | 2016-01-27 | 浙江科源化工有限公司 | 一种2-氨基-n-(2-氯-6-甲基苯基)噻唑-5-甲酰胺的合成方法 |
| IN2013MU03610A (pl) | 2013-12-18 | 2015-04-24 | Dharmesh Mahendrabhai Shah | |
| CZ306732B6 (cs) * | 2013-12-19 | 2017-05-31 | Zentiva, K.S. | Způsob přípravy bezvodé polymorfní formy N-6 Dasatinibu |
| AU2015200822A1 (en) | 2014-03-11 | 2015-10-01 | Cerbios-Pharma Sa | Process and intermediates for the preparation of dasatinib |
| RU2567537C1 (ru) * | 2014-04-23 | 2015-11-10 | Олег Ростиславович Михайлов | Кристаллическая безводная дельта-модификация n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида, способ ее получения и фармацевтическая композиция на ее основе |
| HU231013B1 (hu) * | 2014-05-26 | 2019-11-28 | Egis Gyógyszergyár Zrt. | Dasatinib sók |
| WO2017002131A1 (en) * | 2015-06-29 | 2017-01-05 | Msn Laboratories Private Limited | Crystalline forms of n-(2-chloro-6-methy]phenvn-2-[f6-[4-(2-hvdroxvethvl)-l- piperazinvil-2-methvl-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof |
| WO2017098391A1 (en) * | 2015-12-11 | 2017-06-15 | Shilpa Medicare Limited | Process for the preparation of dasatinib |
| CN105474831B (zh) * | 2015-12-16 | 2017-11-17 | 湖南省西瓜甜瓜研究所 | 一种白芨裸种消毒方法 |
| WO2017108605A1 (en) | 2015-12-22 | 2017-06-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous dasatinib |
| CN105503854A (zh) * | 2015-12-31 | 2016-04-20 | 哈药集团技术中心 | 一种达沙替尼无水合物的新晶型物及其制备方法 |
| BR112018015891A2 (pt) | 2016-02-03 | 2018-12-26 | Dr Reddys Laboratories Ltd | formas de estado sólido de dasatinib e processos para sua preparação |
| WO2017144109A1 (en) | 2016-02-25 | 2017-08-31 | Remedica Ltd | Dasatinib formulation |
| CN105830582B (zh) * | 2016-04-15 | 2018-05-01 | 成都大学 | 一种白及种子的快速回土培育方法 |
| GB201608587D0 (en) | 2016-05-16 | 2016-06-29 | Univ Dundee | Treatment of opiod tolerance |
| CN106117195A (zh) * | 2016-06-09 | 2016-11-16 | 青岛辰达生物科技有限公司 | 一种用于治疗白血病的药物达沙替尼的合成方法 |
| IT201700006145A1 (it) | 2017-01-20 | 2018-07-20 | Cerbios Pharma Sa | Co-cristallo di un composto antitumorale |
| IT201700006157A1 (it) * | 2017-01-20 | 2018-07-20 | Cerbios Pharma Sa | Co-cristalli di un composto antitumorale |
| JP6597727B2 (ja) | 2017-05-11 | 2019-10-30 | 東洋インキＳｃホールディングス株式会社 | 表面保護用粘着剤および粘着シート |
| RU2020105723A (ru) * | 2017-07-07 | 2021-08-09 | Биокон Лимитед | Полиморфные формы дазатиниба |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CA3128468A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| TWI815137B (zh) | 2018-06-15 | 2023-09-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽之結晶 |
| CN109369638B (zh) * | 2018-11-21 | 2020-07-07 | 山东罗欣药业集团股份有限公司 | 一种达沙替尼的制备工艺 |
| CN109503568B (zh) * | 2018-12-29 | 2020-08-07 | 山东罗欣药业集团股份有限公司 | 一种达沙替尼的制备方法 |
| CN112409349A (zh) * | 2019-08-20 | 2021-02-26 | 湖南华纳大药厂股份有限公司 | 激酶抑制剂及其制备、药物组合物和用途 |
| EP4093379A1 (en) | 2020-01-24 | 2022-11-30 | Nanocopoeia LLC | Amorphous solid dispersions of dasatinib and uses thereof |
| GB2592680A (en) | 2020-03-06 | 2021-09-08 | Zentiva Ks | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof |
| EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
| CN114634421A (zh) * | 2022-02-24 | 2022-06-17 | 济宁晟泰药业有限公司 | 一种达沙替尼中间体的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547917A (en) * | 1966-12-07 | 1970-12-15 | Uniroyal Inc | 2-amino-4-methylthiazole-5-carboxamides |
| US5514643A (en) * | 1993-08-16 | 1996-05-07 | Lucky Ltd. | 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms |
| BR0009721A (pt) * | 1999-04-15 | 2002-02-13 | Bristol Myers Squibb Co | Inibidores de tirosina quinase de proteìna cìclica |
| US7169771B2 (en) * | 2003-02-06 | 2007-01-30 | Bristol-Myers Squibb Company | Thiazolyl-based compounds useful as kinase inhibitors |
| EP2260849A1 (en) * | 2004-01-21 | 2010-12-15 | Emory University | Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection |
| TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
-
2005
- 2005-02-01 TW TW094103090A patent/TWI338004B/zh active
- 2005-02-04 IN IN6567DEN2014 patent/IN2014DN06567A/en unknown
- 2005-02-04 PE PE2005000128A patent/PE20050691A1/es active IP Right Grant
- 2005-02-04 KR KR1020067015839A patent/KR101310427B1/ko active IP Right Review Request
- 2005-02-04 ES ES05722772T patent/ES2337272T5/es active Active
- 2005-02-04 WO PCT/US2005/003728 patent/WO2005077945A2/en active Application Filing
- 2005-02-04 BR BRPI0507476A patent/BRPI0507476B8/pt active IP Right Grant
- 2005-02-04 CA CA2555291A patent/CA2555291C/en active Active
- 2005-02-04 DE DE602005018601T patent/DE602005018601D1/de active Active
- 2005-02-04 AU AU2005212405A patent/AU2005212405B2/en active Active
- 2005-02-04 NZ NZ548613A patent/NZ548613A/en unknown
- 2005-02-04 RU RU2006131591/04A patent/RU2382039C2/ru active
- 2005-02-04 JP JP2006552303A patent/JP5148115B2/ja active Active
- 2005-02-04 PL PL05722772T patent/PL1711481T5/pl unknown
- 2005-02-04 PT PT05722772T patent/PT1711481E/pt unknown
- 2005-02-04 DK DK05722772.0T patent/DK1711481T4/da active
- 2005-02-04 AR ARP050100427A patent/AR047533A1/es not_active Application Discontinuation
- 2005-02-04 SI SI200530905T patent/SI1711481T2/sl unknown
- 2005-02-04 AT AT05722772T patent/ATE453630T1/de active
- 2005-02-04 EP EP05722772.0A patent/EP1711481B2/en active Active
- 2005-02-04 KR KR1020127021611A patent/KR20120097424A/ko not_active Application Discontinuation
- 2005-02-04 GE GEAP20059607A patent/GEP20094804B/en unknown
-
2006
- 2006-07-27 ZA ZA2006/06242A patent/ZA200606242B/en unknown
- 2006-08-03 IL IL177280A patent/IL177280A/en active IP Right Grant
- 2006-08-24 NO NO20063780A patent/NO338049B1/no unknown
- 2006-11-23 HK HK06112879.5A patent/HK1091835A1/xx active IP Right Maintenance
-
2010
- 2010-03-19 CY CY20101100253T patent/CY1109907T1/el unknown
- 2010-03-22 HR HRP20100166TT patent/HRP20100166T4/hr unknown
-
2012
- 2012-06-06 JP JP2012129253A patent/JP2012188446A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN06567A (pl) | ||
| WO2005076990A3 (en) | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors | |
| WO2006050109A3 (en) | Novel kinase inhibitors | |
| TNSN06405A1 (en) | Quinazolinone derivatives useful as vanilloid antagonistes | |
| WO2006017054A3 (en) | Tricyclic-heteroaryl compounds useful as kinase inhibitors | |
| TW200744604A (en) | P38 MAP kinase inhibitors and methods for using the same | |
| HK1110588A1 (en) | Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase | |
| TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
| EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
| GEP20094785B (en) | Pyrrolopyrazoles, potent kinase inhibitors | |
| TW200621721A (en) | Methods of preparing indazole compounds | |
| MX2008005398A (es) | Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer. | |
| DK1648905T3 (da) | Inhibitorer for thienopyridin- og furopyridinkinase | |
| MXPA05013076A (es) | Compuestos de isoindolina-1-ona como inhibidores de cinasa. | |
| MXPA05010440A (es) | Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b). | |
| WO2004030620A3 (en) | Novel tyrosine kinase inhibitors | |
| TW200740816A (en) | P38 MAP kinase inhibitors and methods for using the same | |
| UA85394C2 (ru) | Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ | |
| BRPI0509731A (pt) | pirazol[4,3-d]pirimidinas | |
| WO2004092144A3 (en) | Quinazoline compounds useful as p38 kinase inhibitors | |
| MXPA05009151A (es) | Inhibidores de cinasa heterociclica. | |
| TNSN06260A1 (en) | Process for the preparation of tryptase inhibitors | |
| TW200628153A (en) | Novel compounds | |
| DE602004005881D1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
| WO2005097755A3 (de) | Imidazolderivate als hemmer von tyrosinkinase |